For adults juggling multiple cardiovascular medications, the promise of a single daily pill replacing several has enormous appeal — not just for convenience, but potentially for lives saved. This analysis of nearly 28,000 trial participants offers the most rigorous picture yet of where that promise holds up and where it falls short, with implications for how clinicians and patients think about adherence-driven prevention strategies.

This meta-analysis pooled data from 13 randomized controlled trials enrolling 27,836 participants across both primary and secondary cardiovascular prevention settings. Polypills — fixed-dose combinations typically bundling a statin, one or more antihypertensives, and sometimes aspirin — produced a statistically meaningful 31% relative reduction in cardiovascular death (RR 0.69, 95% CI 0.57–0.83) and a 31% reduction in myocardial infarction risk (RR 0.69, 95% CI 0.50–0.95). Stroke risk fell by 39% in the four trials that measured it. However, the headline metric — all-cause mortality — showed no significant benefit (RR 0.93, 95% CI 0.82–1.05). Heart failure events and revascularization rates were similarly unaffected. Polypills did produce small but statistically significant reductions in systolic and diastolic blood pressure, total cholesterol, and LDL, and adverse event rates increased only marginally and non-significantly.

The cardiovascular mortality reduction is clinically meaningful, but the absence of an all-cause mortality signal warrants careful interpretation. It may reflect study duration limits, competing non-cardiovascular causes of death in trial populations, or residual confounding. The stroke finding is particularly striking given that only four trials contributed to that estimate — replication in larger, longer studies is essential before it reshapes guidelines. The polypill concept aligns well with adherence research showing that pill burden is a major driver of non-compliance; the true long-term benefit may only emerge in real-world populations where adherence advantages compound over decades. Limitations include heterogeneity across polypill formulations, trial populations spanning very different baseline risk profiles, and variable follow-up periods. Overall, this meta-analysis is confirmatory rather than paradigm-shifting for secondary prevention, but meaningfully strengthens the case for polypills in high-risk primary prevention populations who struggle with multi-drug regimens.